Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The potential for aromatase inhibition in breast cancer prevention.
Lønning PE, Kragh LE, Erikstein B, Hagen A, Risberg T, Schlichting E, Geisler J. Lønning PE, et al. Among authors: erikstein b. Clin Cancer Res. 2001 Dec;7(12 Suppl):4423s-4428s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916235 Review.
Genetic variants of CYP19 (aromatase) and breast cancer risk.
Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Kåresen R, Kristensen T, Børresen-Dale AL. Kristensen VN, et al. Among authors: erikstein b. Oncogene. 2000 Mar 2;19(10):1329-33. doi: 10.1038/sj.onc.1203425. Oncogene. 2000. PMID: 10713674
Screening breast cancer patients for Norwegian ATM mutations.
Laake K, Vu P, Andersen TI, Erikstein B, Kåresen R, Lonning PE, Skovlund E, Børresen-Dale AL. Laake K, et al. Among authors: erikstein b. Br J Cancer. 2000 Dec;83(12):1650-3. doi: 10.1054/bjoc.2000.1519. Br J Cancer. 2000. PMID: 11104561 Free PMC article.
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C. Howell A, et al. Among authors: erikstein b. J Clin Oncol. 2002 Aug 15;20(16):3396-403. doi: 10.1200/JCO.2002.10.057. J Clin Oncol. 2002. PMID: 12177099 Clinical Trial.
Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, Kaasa S, Nilsson J, Wiklund T, Wilking N, Bergh J; Scandinavian Breast Group Study 9401. Brandberg Y, et al. Among authors: erikstein b. J Clin Oncol. 2003 Oct 1;21(19):3659-64. doi: 10.1200/JCO.2003.07.020. J Clin Oncol. 2003. PMID: 14512398 Clinical Trial.
61 results